The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Pricing and reimbursement of orphan drugs: the need for more transparency
Open accessAbstract
Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients. This study aims to conduct a literature review to provide insight into the drivers of orphan drug pricing and reimbursement. Although orphan drug pricing follows the same economic logic as drug pricing in general, the monopolistic power of orphan drugs results in high prices: a) orphan drugs benefit from a period of marketing exclusivity; b) few alternative health technologies are available; c) third-party payers and patients have limited negotiating power; d) manufacturers attempt to maximise orphan drug prices within the constraints of domestic pricing and reimbursement policies; and e) substantial R&D costs need to be recouped from a small number of patients. Although these conditions apply to some orphan drugs, they do not apply to all orphan drugs. Indeed, the small number of patients treated with an orphan drug and the limited economic viability of orphan drugs can be questioned in a number of cases. Additionally, manufacturers have an incentive to game the system by artificially creating monopolistic market conditions. Given their high price for an often modest effectiveness, orphan drugs are unlikely to provide value for money. However, additional criteria are used to inform reimbursement decisions in some countries. These criteria may include: the seriousness of the disease; the availability of other therapies to treat the disease; and the cost to the patient if the medicine is not reimbursed. Therefore, the maximum cost per unit of outcome that a health care payer is willing to pay for a drug could be set higher for orphan drugs to which society attaches a high social value. There is a need for a transparent and evidence-based approach towards orphan drug pricing and reimbursement. Such an approach should be targeted at demonstrating the relative effectiveness, cost-effectiveness and economic viability of orphan drugs with a view to informing pricing and reimbursement decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Institute for Clinical Excellence and its value judgments
Rawlins, M. D., & Culyer, A. J. (2004) · BMJ · doi:10.1136/bmj.329.7459.224 · Cited by 765
QALY maximisation and people's preferences: a methodological review of the literature
Dolan, P., Shaw, R., Tsuchiya, A., & Williams, A. (2005) · Health Economics · doi:10.1002/hec.924 · Cited by 431
George, B., Harris, A., & Mitchell, A. (2001) · PharmacoEconomics · doi:10.2165/00019053-200119110-00004 · Cited by 431
Assessing the economic challenges posed by orphan drugs
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462307051550 · Cited by 279
Orphan drugs and the NHS: should we value rarity?
McCabe, C., Claxton, K., & Tsuchiya, A. (2005) · BMJ · doi:10.1136/bmj.331.7523.1016 · Cited by 229
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes, D. A., Tunnage, B., & Yeo, S. T. (2005) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hci128 · Cited by 219
Rare diseases, orphan drugs and their regulation: questions and misconceptions
Tambuyzer, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3275 · Cited by 182
Regnström, J., König, F., Aronsson, B., Reimer, T., Svendsen, K., Tsigkos, S., Flamion, B., Eichler, H., & Vamvakas, S. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0756-y · Cited by 128
Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
Desser, A. S., Gyrd‐Hansen, D., Olsen, J. A., Grepperud, S., & Kristiansen, I. S. (2010) · BMJ · doi:10.1136/bmj.c4715 · Cited by 111
Scottish Medicines Consortium.
KOHLI, H. S. (2005) · PubMed · Cited by 108
Cited by
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Gammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0140002 · Cited by 277
Gene Therapies: The Challenge of sUper-High-Cost Treatments and How to Pay for them
Carr, D. R., & Bradshaw, S. E. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0010 · Cited by 58
Metadata
- Authors
- Simoens, S.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2011
- Volume
- 6
- Issue
- 1
- Pages
- 42
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2131080517
- Cited by
- 260
- References
- 20
- FWCI
- 45.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pricing and reimbursement of orphan drugs: the need for more transparency. https://app.cochat.ai/papers/10.1186/1750-1172-6-42
- The paper
- Simoens, S. (2011). Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-6-42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.